3. AtriCure
R&D spend: $35.8 million
Percent of revenues: 23.1%
2017 overall revenue rank: 98
AtriCure (Nasdaq: ATRC), is an innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management. The Mason, Ohio–based company in September launched its AtriClip Pro-V left atrial appendage exclusion system. The AtriClip Pro-V has an open-ended design combined with a tip-first closure mechanism. The idea is to enable easier navigation and placement during minimally-invasive surgery.